Stocks
Asensus Surgical Financial Statements (ASXC) |
||||||||||
| Asensus Surgicalsmart-lab.ru | % | 2021 | 2022 | 2022 | 2023 | LTM ? | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2022 | 30.06.2022 | 31.12.2022 | 02.03.2023 | 21.03.2024 | 14.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 8.23 | 7.09 | 7.09 | 8.58 | 8.72 | ||||
| Operating Income, bln rub | -64.6 | -75.7 | -75.7 | -78.1 | -74.1 | |||||
| EBITDA, bln rub | ? | -48.9 | -63.8 | -63.4 | -74.4 | -70.8 | ||||
| Net profit, bln rub | ? | -62.5 | -75.6 | -75.6 | -78.4 | -78.7 | ||||
| OCF, bln rub | ? | -40.7 | -58.9 | -58.9 | -63.6 | -60.4 | ||||
| CAPEX, bln rub | ? | 1.37 | 1.28 | 1.28 | 0.561 | 0.497 | ||||
| FCF, bln rub | ? | -42.0 | -60.2 | -60.2 | -64.2 | -60.9 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0 | |||||
| OPEX, bln rub | 61.8 | 71.9 | 71.6 | 73.1 | 69.2 | |||||
| Cost of production, bln rub | 11.1 | 10.9 | 10.9 | 13.6 | 13.5 | |||||
| R&D, bln rub | 19.3 | 28.9 | 28.9 | 37.0 | 35.0 | |||||
| Interest expenses, bln rub | 0.370 | 0.410 | 0.410 | 0.000 | 0.178 | |||||
| Assets, bln rub | 186.5 | 147.4 | 116.1 | 116.1 | 60.5 | 40.8 | ||||
| Net Assets, bln rub | ? | 169.2 | 131.4 | 99.6 | 99.6 | 33.4 | 13.0 | |||
| Debt, bln rub | 12.1 | 5.19 | 5.54 | 5.54 | 5.68 | 5.46 | ||||
| Cash, bln rub | 98.4 | 94.2 | 70.5 | 70.5 | 21.1 | 7.99 | ||||
| Net debt, bln rub | -86.3 | -89.0 | -65.0 | -65.0 | -15.4 | -2.53 | ||||
| Ordinary share price, rub | 1.11 | 0.400 | 0.347 | 0.347 | 0.319 | |||||
| Number of ordinary shares, mln | 227.0 | 236.5 | 236.5 | 249.7 | 269.3 | |||||
| Market cap, bln rub | 252 | 0 | 82 | 82 | 80 | 0 | ||||
| EV, bln rub | ? | 166 | -89 | 17 | 17 | 64 | -3 | |||
| Book value, bln rub | 169 | 131 | 100 | 98 | 32 | 12 | ||||
| EPS, rub | ? | -0.28 | -0.32 | -0.32 | -0.31 | -0.29 | ||||
| FCF/share, rub | -0.19 | -0.25 | -0.25 | -0.26 | -0.23 | |||||
| BV/share, rub | 0.75 | 0.42 | 0.41 | 0.13 | 0.04 | |||||
| EBITDA margin, % | ? | -594.6% | -899.6% | -895.2% | -867.4% | -812.1% | ||||
| Net margin, % | ? | -758.8% | -1 066% | -1 066% | -914.5% | -902.2% | ||||
| FCF yield, % | ? | -16.7% | 0.00% | -73.4% | -73.4% | -80.6% | ||||
| ROE, % | ? | -36.9% | 0.00% | -75.8% | -75.8% | -234.7% | -604.4% | |||
| ROA, % | ? | -33.5% | 0.00% | -65.1% | -65.1% | -129.6% | -192.9% | |||
| P/E | ? | -4.03 | -1.09 | -1.09 | -1.02 | 0 | ||||
| P/FCF | -5.99 | -1.36 | -1.36 | -1.24 | 0 | |||||
| P/S | ? | 30.6 | 11.6 | 11.6 | 9.28 | 0 | ||||
| P/BV | ? | 1.49 | 0.00 | 0.82 | 0.84 | 2.47 | 0 | |||
| EV/EBITDA | ? | -3.38 | -0.27 | -0.27 | -0.86 | 0.04 | ||||
| Debt/EBITDA | 1.76 | 1.02 | 1.02 | 0.21 | 0.04 | |||||
| R&D/CAPEX, % | 1 414% | 2 263% | 2 263% | 6 599% | 7 037% | |||||
| CAPEX/Revenue, % | 16.6% | 18.0% | 18.0% | 6.54% | 5.70% | |||||
| Asensus Surgical shareholders | ||||||||||
